Published in Antimicrob Agents Chemother on September 01, 1999
Human enterovirus 71 epidemics: what's next? Emerg Health Threats J (2013) 1.54
Early B cell defects. Clin Exp Immunol (2000) 1.43
High Frequency of Detection by PCR of Viral Nucleic Acid in The Blood of Infants Presenting with Clinical Myocarditis. Pediatr Cardiol (2015) 1.41
Enterovirus infections of the central nervous system. Virology (2011) 1.24
Molecular dynamics simulations of human rhinovirus and an antiviral compound. Biophys J (2001) 1.22
More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules. Nat Struct Mol Biol (2014) 1.16
Infection and propagation of human rhinovirus C in human airway epithelial cells. J Virol (2012) 1.14
In vitro antiviral activity of V-073 against polioviruses. Antimicrob Agents Chemother (2009) 1.13
Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone. Antimicrob Agents Chemother (2004) 1.12
Enteroviral meningitis: natural history and outcome of pleconaril therapy. Antimicrob Agents Chemother (2006) 1.06
In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob Agents Chemother (2004) 1.05
Long-distance correlations of rhinovirus capsid dynamics contribute to uncoating and antiviral activity. Proc Natl Acad Sci U S A (2012) 0.96
Immune responses and the emergence of drug-resistant virus strains in vivo. Proc Biol Sci (2004) 0.96
Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects. PLoS Pathog (2012) 0.95
The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication. Antimicrob Agents Chemother (2014) 0.94
Neonatal coxsackie B virus infection-a treatable disease? Eur J Pediatr (2004) 0.93
An RNA replication-center assay for high content image-based quantifications of human rhinovirus and coxsackievirus infections. Virol J (2010) 0.93
An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus. ACS Med Chem Lett (2012) 0.92
An anti-human ICAM-1 antibody inhibits rhinovirus-induced exacerbations of lung inflammation. PLoS Pathog (2013) 0.91
Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host. Virology (2015) 0.91
Characterization of poliovirus variants selected for resistance to the antiviral compound V-073. Antimicrob Agents Chemother (2012) 0.91
Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus. Antimicrob Agents Chemother (2004) 0.90
Severe hepatitis associated with an echovirus 18 infection in an immune-compromised adult. J Clin Microbiol (2012) 0.89
Replication and Inhibitors of Enteroviruses and Parechoviruses. Viruses (2015) 0.89
Picornavirus morphogenesis. Microbiol Mol Biol Rev (2014) 0.88
In Vitro Efficacy of Antiviral Compounds against Enterovirus D68. Antimicrob Agents Chemother (2015) 0.86
Recent progress in understanding coxsackievirus replication, dissemination, and pathogenesis. Virology (2015) 0.86
Recent developments in antiviral agents against enterovirus 71 infection. J Biomed Sci (2014) 0.85
Inhibition of enterovirus 71 (EV-71) infections by a novel antiviral peptide derived from EV-71 capsid protein VP1. PLoS One (2012) 0.84
Genetic diversity of a Korean echovirus 5 isolate and response of the strain to five antiviral drugs. Virol J (2011) 0.80
Therapeutic and prevention strategies against human enterovirus 71 infection. World J Virol (2015) 0.77
Potent antiviral agents fail to elicit genetically-stable resistance mutations in either enterovirus 71 or Coxsackievirus A16. Antiviral Res (2015) 0.77
Molecular characterization and antiviral activity test of common drugs against echovirus 18 isolated in Korea. Virol J (2011) 0.76
Pyrazolopyrimidines: Potent Inhibitors Targeting the Capsid of Rhino- and Enteroviruses. ChemMedChem (2015) 0.76
Enterovirus infection in Korean children and anti-enteroviral potential candidate agents. Korean J Pediatr (2012) 0.75
Diagnosis and Management of Enteroviral Infections of the Central Nervous System. Curr Infect Dis Rep (2002) 0.75
Crystal structure of 5-{3-[2,6-dimethyl-4-(5-methyl-1,2,4-oxa-diazol-3-yl)phen-oxy]prop-yl}-N-(11-hy-droxy-undec-yl)isoxazole-3-carboxamide hemihydrate. Acta Crystallogr E Crystallogr Commun (2015) 0.75
Potent inhibition of enterovirus D68 and human rhinoviruses by dipeptidyl aldehydes and α-ketoamides. Antiviral Res (2015) 0.75
Treatment of perinatal viral infections to improve neurologic outcomes. Pediatr Res (2016) 0.75
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 114.35
The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science (1986) 4.40
Temporal and geographic patterns of isolates of nonpolio enterovirus in the United States, 1970-1983. J Infect Dis (1986) 3.01
The structure of coxsackievirus B3 at 3.5 A resolution. Structure (1995) 2.73
Antiviral agent blocks breathing of the common cold virus. Proc Natl Acad Sci U S A (1998) 2.71
Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors. J Virol (1989) 2.61
Crystal structure of human rhinovirus serotype 1A (HRV1A). J Mol Biol (1989) 2.49
Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis. Clin Microbiol Rev (1998) 2.48
In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother (1985) 2.44
Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc Natl Acad Sci U S A (1988) 2.30
Detection of enteroviruses and rhinoviruses in clinical specimens by PCR and liquid-phase hybridization. J Clin Microbiol (1995) 2.10
Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev Infect Dis (1987) 2.06
Properties of coxsackievirus B3 variants which are amyocarditic or myocarditic for mice. J Med Virol (1979) 1.94
The refined structure of human rhinovirus 16 at 2.15 A resolution: implications for the viral life cycle. Structure (1997) 1.82
Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment. Annu Rev Microbiol (1992) 1.41
A novel basis of capsid stabilization by antiviral compounds. J Mol Biol (1995) 1.35
A comparison of the anti-rhinoviral drug binding pocket in HRV14 and HRV1A. J Mol Biol (1993) 1.32
Encephalomyelitis in primary hypogammaglobulinaemia. Brain (1996) 1.25
Influence of an antiviral compound on the temperature dependence of viral protein flexibility and packing: a molecular dynamics study. J Mol Biol (1998) 1.22
In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother (1989) 1.22
Perinatal echovirus infection: insights from a literature review of 61 cases of serious infection and 16 outbreaks in nurseries. Rev Infect Dis (1987) 1.17
Profile of enterovirus disease in the first two weeks of life. Pediatr Infect Dis J (1993) 1.17
Attenuated virulence of pleconaril-resistant coxsackievirus B3 variants. J Infect Dis (1999) 1.15
Oxadiazoles as ester bioisosteric replacements in compounds related to disoxaril. Antirhinovirus activity. J Med Chem (1994) 1.02
Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism. J Med Chem (1995) 1.02
Rhinovirus infection associated with serious lower respiratory illness in patients with bronchopulmonary dysplasia. Pediatr Infect Dis J (1997) 1.01
Serious respiratory illness associated with rhinovirus infection in a pediatric population. Clin Diagn Virol (1998) 1.00
A model for compounds active against human rhinovirus-14 based on X-ray crystallography data. J Med Chem (1990) 0.91
Conformationally restricted analogues of disoxaril: a comparison of the activity against human rhinovirus types 14 and 1A. J Med Chem (1992) 0.87
CoMFA analysis of the interactions of antipicornavirus compounds in the binding pocket of human rhinovirus-14. J Med Chem (1992) 0.84
Antipicornavirus activity of tetrazole analogues related to disoxaril. J Med Chem (1993) 0.83
Antipicornavirus activity of some diaryl methanes and aralkylaminopyridines. Antiviral Res (1987) 0.82
[(Biaryloxy)alkyl]isoxazoles: picornavirus inhibitors. J Med Chem (1995) 0.79
Antirhinoviral activity of heterocyclic analogs of Win 54954. J Med Chem (1992) 0.79
Single oral dose escalation pharmacokinetics of pleconaril (VP 63843) capsules in adults. J Clin Pharmacol (1999) 0.79
The nucleotide sequences of the rbsD, rbsA, and rbsC genes of Escherichia coli K12. J Biol Chem (1986) 1.90
Ribokinase from Escherichia coli K12. Nucleotide sequence and overexpression of the rbsK gene and purification of ribokinase. J Biol Chem (1986) 1.39
The amino acid sequence of D-ribose-binding protein from Escherichia coli K12. J Biol Chem (1983) 1.24
A signal sequence mutant defective in export of ribose-binding protein and a corresponding pseudorevertant isolated without imposed selection. EMBO J (1985) 0.93